Two university hospitals are pioneering new ways to expand lifesaving heart transplants for adults and babies—advances that could help recover would-be heart donations that too often go unused.
A scientific team supported in part by the National Institutes of Health (NIH) has developed a new, ultra-high-resolution brain imaging system that can reconstruct microscopic brain structures that are disrupted in neurological and neuropsychiatric brain disorders.
Duke Health has pioneered a world’s-first technique that could expand the donor pool for pediatric heart transplants in the U.S. by up to 20%—offering new hope to families on the waitlist.
Sensome, the pioneer of microsensing technology for real-time, in situ tissue analysis, today announced the publication of a study in Science Advances unveiling an innovative methodology using its technology to noninvasively monitor cell spatiotemporal dynamics involved in cancer progression in a real-time and label-free manner, which can provide new insights for cancer diagnosis and treatment.
Artificial intelligence (AI) models trained on large datasets are increasingly seen as the key to unlocking personalized treatments for brain disorders. An important bottleneck for scaling AI is the cost of data collection. This raises a fundamental dilemma: is it more cost-effective to scan more people for a short time, or fewer people for longer?
Scientists have used an AI model to reassess the results of a completed clinical trial for an Alzheimer’s disease drug. They found that the drug slowed cognitive decline by 46% in a group of patients with early-stage, slow-progressing mild cognitive impairment—a condition that can progress to Alzheimer’s.
A specially engineered antibody that can accurately deliver RNA treatments into hard-to-reach and hard-to-treat tumors significantly improved survival and reduced tumor sizes in animal models, according to a study reported in Science Translational Medicine.
The FDA approval of Thermo Fisher’s Oncomine Dx Express Test marks a key advancement in precision oncology, enabling fast, accurate detection of EGFR exon 20 insertion mutations and guiding NSCLC patients to targeted treatments like ZEGFROVY.
Next-Generation Platform Enhances Endoscopic Ultrasound Imaging to Support More Accurate and Efficient Diagnoses
SAN FRANCISCO, July 16, 2025 /PRNewswire/ — Piccolo Medical, Inc. (Piccolo), a leading innovator in vascular access technology, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its next-generation SmartPICC® Stylet and PM2+™ System. This significant achievement marks a major leap forward in safe, efficient, and cost-effective peripherally inserted central catheter (PICC) placement, offering enhanced benefits for both patients and healthcare providers.